S&P 500   3,300.55 (+1.66%)
DOW   27,186.61 (+1.38%)
QQQ   271.42 (+2.27%)
AAPL   111.97 (+3.47%)
MSFT   208.24 (+2.49%)
FB   254.62 (+2.04%)
GOOGL   1,439.89 (+1.20%)
AMZN   3,088.00 (+2.26%)
TSLA   403.83 (+4.14%)
NVDA   512.31 (+3.72%)
BABA   270.41 (+0.25%)
CGC   14.12 (-1.05%)
GE   6.13 (+1.16%)
MU   49.05 (-0.85%)
AMD   77.96 (+2.82%)
T   27.99 (-0.18%)
F   6.53 (-1.95%)
ACB   5.01 (-3.65%)
GILD   62.31 (+0.10%)
NFLX   483.45 (+2.19%)
DIS   123.59 (+0.90%)
BAC   23.45 (+0.47%)
BA   154.66 (+5.90%)
S&P 500   3,300.55 (+1.66%)
DOW   27,186.61 (+1.38%)
QQQ   271.42 (+2.27%)
AAPL   111.97 (+3.47%)
MSFT   208.24 (+2.49%)
FB   254.62 (+2.04%)
GOOGL   1,439.89 (+1.20%)
AMZN   3,088.00 (+2.26%)
TSLA   403.83 (+4.14%)
NVDA   512.31 (+3.72%)
BABA   270.41 (+0.25%)
CGC   14.12 (-1.05%)
GE   6.13 (+1.16%)
MU   49.05 (-0.85%)
AMD   77.96 (+2.82%)
T   27.99 (-0.18%)
F   6.53 (-1.95%)
ACB   5.01 (-3.65%)
GILD   62.31 (+0.10%)
NFLX   483.45 (+2.19%)
DIS   123.59 (+0.90%)
BAC   23.45 (+0.47%)
BA   154.66 (+5.90%)
S&P 500   3,300.55 (+1.66%)
DOW   27,186.61 (+1.38%)
QQQ   271.42 (+2.27%)
AAPL   111.97 (+3.47%)
MSFT   208.24 (+2.49%)
FB   254.62 (+2.04%)
GOOGL   1,439.89 (+1.20%)
AMZN   3,088.00 (+2.26%)
TSLA   403.83 (+4.14%)
NVDA   512.31 (+3.72%)
BABA   270.41 (+0.25%)
CGC   14.12 (-1.05%)
GE   6.13 (+1.16%)
MU   49.05 (-0.85%)
AMD   77.96 (+2.82%)
T   27.99 (-0.18%)
F   6.53 (-1.95%)
ACB   5.01 (-3.65%)
GILD   62.31 (+0.10%)
NFLX   483.45 (+2.19%)
DIS   123.59 (+0.90%)
BAC   23.45 (+0.47%)
BA   154.66 (+5.90%)
S&P 500   3,300.55 (+1.66%)
DOW   27,186.61 (+1.38%)
QQQ   271.42 (+2.27%)
AAPL   111.97 (+3.47%)
MSFT   208.24 (+2.49%)
FB   254.62 (+2.04%)
GOOGL   1,439.89 (+1.20%)
AMZN   3,088.00 (+2.26%)
TSLA   403.83 (+4.14%)
NVDA   512.31 (+3.72%)
BABA   270.41 (+0.25%)
CGC   14.12 (-1.05%)
GE   6.13 (+1.16%)
MU   49.05 (-0.85%)
AMD   77.96 (+2.82%)
T   27.99 (-0.18%)
F   6.53 (-1.95%)
ACB   5.01 (-3.65%)
GILD   62.31 (+0.10%)
NFLX   483.45 (+2.19%)
DIS   123.59 (+0.90%)
BAC   23.45 (+0.47%)
BA   154.66 (+5.90%)
Log in
OTCMKTS:UCBJY

UCB S A/ADR Stock Forecast, Price & News

$57.36
-0.67 (-1.15 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$56.65
Now: $57.36▼
$57.76
50-Day Range
$56.77
MA: $59.08▼
$63.20
52-Week Range
$32.45
Now: $57.36▼
$68.00
Volume4,958 shs
Average Volume13,040 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
UCB SA, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes biopharmaceutical solutions for people living with neurology and immunology conditions. The company's core products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company's product pipeline includes Evenity for the treatment of osteoporosis; midazolam nasal spray to treat acute repetitive seizures; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 and UCB0159 for immunology; and UCB0599 and UCB0107 for neurology. Additionally, the company engages in contract manufacturing activities. UCB SA has collaboration agreements with Sanofi and Otsuka. The company was founded in 1928 and is headquartered in Brussels, Belgium.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.52 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:UCBJY
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.ucb.com
Phone32 2 559 99 99

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees6,828
Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
$57.36
-0.67 (-1.15 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UCBJY News and Ratings via Email

Sign-up to receive the latest news and ratings for UCBJY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











UCB S A/ADR (OTCMKTS:UCBJY) Frequently Asked Questions

How has UCB S A/ADR's stock been impacted by Coronavirus?

UCB S A/ADR's stock was trading at $50.3225 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, UCBJY stock has increased by 14.0% and is now trading at $57.36.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of UCB S A/ADR?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB S A/ADR in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for UCB S A/ADR.

Are investors shorting UCB S A/ADR?

UCB S A/ADR saw a drop in short interest in August. As of August 31st, there was short interest totaling 500 shares, a drop of 73.7% from the August 15th total of 1,900 shares. Based on an average daily volume of 9,000 shares, the days-to-cover ratio is presently 0.1 days.
View UCB S A/ADR's Short Interest.

Who are some of UCB S A/ADR's key competitors?

Some companies that are related to UCB S A/ADR include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Acrux (ACR), Actinogen Medical (ACW), Adalta (1AD), Admedus (AHZ), Almirall (LBTSF), Amarantus Bioscience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR), Antibe Therapeutics (VBIZF), Aortech International (RUA), Apotheca Biosciences (CBDC) and Arno Therapeutics (ARNI).
View all competitors.

Who are UCB S A/ADR's key executives?

UCB S A/ADR's management team includes the following people:
  • Mr. Jean-Christophe Tellier, CEO & Exec. Director (Age 60)
  • Mr. Detlef Thielgen, CFO & Exec. VP (Age 59)
  • Mr. Charl Van Zyl, COO & Exec. VP (Age 52)
  • Dr. Dhavalkumar D. Patel, Exec. VP & Chief Scientific Officer (Age 58)
  • Dr. Bharat Tewarie, Chief Marketing Officer & Exec. VP (Age 58)

What is UCB S A/ADR's stock symbol?

UCB S A/ADR trades on the OTCMKTS under the ticker symbol "UCBJY."

How do I buy shares of UCB S A/ADR?

Shares of UCBJY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is UCB S A/ADR's stock price today?

One share of UCBJY stock can currently be purchased for approximately $57.36.

What is UCB S A/ADR's official website?

The official website for UCB S A/ADR is www.ucb.com.

How can I contact UCB S A/ADR?

The company can be reached via phone at 32 2 559 99 99.

This page was last updated on 9/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.